Kantonsspital Graubuenden

Futó vizsgálatok

• Toboroz

  Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07149649· 2/3. fázis· Forrás

• Toboroz

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· 2. fázis· Forrás

• Toboroz

  Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

  NCT07020065· 2. fázis· Forrás

• Toboroz

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· 1. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· 3. fázis· Forrás

• Toboroz

  Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

  NCT05815927· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· 3. fázis· Forrás

• Toboroz

  Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06401980· 2. fázis· Forrás

• Toboroz

  Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

  NCT06598306· 1. fázis· Forrás

• Fut, nem toboroz

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· 3. fázis· Forrás

• Toboroz

  Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

  NCT06114108· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· 3. fázis· Forrás

• Fut, nem toboroz

  Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

  NCT04630730· 2. fázis· Forrás

• Fut, nem toboroz

  Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

  NCT04472949· 2. fázis· Forrás

• Fut, nem toboroz

  Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

  NCT04245514· 2. fázis· Forrás

• Toboroz

  E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

  NCT03818503· Forrás

• Fut, nem toboroz

  1st Line Durvalumab in PS 2 NSCLC Patients

  NCT03620669· 2. fázis· Forrás

• Fut, nem toboroz

  Prostate Cancer Biobank

  NCT04024475· Forrás

• Fut, nem toboroz

  Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

  NCT00268476· 2/3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák5 toboroz
• Prosztatarák2 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyermekkori daganatok1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· 1/2. fázis· Forrás

• Leállították

  Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

  NCT04629781· 1. fázis· Forrás

• Lezárult

  SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

  NCT04480372· 2. fázis· Forrás

• Lezárult

  Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

  NCT04362072· 4. fázis· Forrás

• Lezárult

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· 3. fázis· Forrás

• Lezárult

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  NCT02910557· Forrás

• Leállították

  ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

  NCT02933801· 2. fázis· Forrás

• Lezárult

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· 2. fázis· Forrás

• Visszavonták

  Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

  NCT02053311· 3. fázis· Forrás

• Toboroz

  AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

  NCT02102165· Forrás

• Lezárult

  Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

  NCT01272050· 3. fázis· Forrás